Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Single, double and even triple-payload ADCs will be presented at the meeting.
Talapro-3 could help move Talzenna into earlier prostate cancer.
First human data on MK-2010 are imminent.
The company reveals its anti-GPRC5D T-cell engager.
The company’s TRPV1 antagonist looks doomed.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
